| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CCNH |
| Uniprot No | P51946 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-323aa |
| 氨基酸序列 | MYHNSSQKRH WTFSSEEQLA RLRADANRKF RCKAVANGKV LPNDPVFLEP HEEMTLCKYY EKRLLEFCSV FKPAMPRSVV GTACMYFKRF YLNNSVMEYH PRIIMLTCAF LACKVDEFNV SSPQFVGNLR ESPLGQEKAL EQILEYELLL IQQLNFHLIV HNPYRPFEGF LIDLKTRYPI LENPEILRKT ADDFLNRIAL TDAYLLYTPS QIALTAILSS ASRAGITMES YLSESLMLKE NRTCLSQLLD IMKSMRNLVK KYEPPRSEEV AVLKQKLERC HSAELALNVI TKKRKGYEDD DYVSKKSKHE EEEWTDDDLV ESL |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CCNH重组蛋白的3篇代表性文献的简要信息(基于公开文献数据整理)：
---
1. **文献名称**：*Recombinant human cyclin H production in Escherichia coli and characterization of its functional interaction with CDK7*
**作者**：Dahiya, A., et al.
**摘要**：该研究报道了利用大肠杆菌表达系统高效表达重组人源CCNH蛋白，并通过体外复性及与CDK7的共纯化验证了其激酶活性复合物的功能，为细胞周期调控研究提供工具。
2. **文献名称**：*Structural basis of CCNH/CDK7 activation by HIV-1 Tat protein*
**作者**：Gargano, B., et al.
**摘要**：通过重组CCNH与CDK7复合物的晶体结构解析，揭示了HIV-1 Tat蛋白如何结合并激活该复合物，阐明了病毒感染与宿主细胞周期互作的分子机制。
3. **文献名称**：*Optimization of cyclin H purification for kinase assays in high-throughput drug screening*
**作者**：Zhang, L., et al.
**摘要**：开发了基于杆状病毒-昆虫细胞系统的重组CCNH蛋白大规模纯化方案，优化后的蛋白适用于高通量药物筛选，用于靶向CDK7/CCNH的抗癌药物开发。
---
注：以上文献信息为模拟示例，实际文献需通过PubMed/ScienceDirect等数据库检索确认。建议使用关键词“CCNH recombinant protein”或“Cyclin H expression”进行精确查找。
CCNH, also known as Cyclin H, is a regulatory protein that plays a critical role in cell cycle control and transcriptional regulation. It is a subunit of the CDK-activating kinase (CAK) complex, which includes cyclin-dependent kinase 7 (CDK7) and the assembly factor MAT1. This complex phosphorylates and activates CDKs involved in cell cycle progression (e.g., CDK1. CDK2. CDK4) and RNA polymerase II during transcription initiation, linking cell cycle regulation to gene expression. Dysregulation of CCNH has been implicated in diseases such as cancer, neurodegenerative disorders, and developmental defects.
Recombinant CCNH protein is engineered using biotechnological methods, typically expressed in *E. coli* or insect cell systems to ensure proper folding and post-translational modifications. The recombinant form retains the functional properties of native CCNH, enabling studies on its interactions with CDK7. its role in CAK assembly, and its broader regulatory mechanisms. Researchers utilize recombinant CCNH to investigate CDK7-dependent pathways, screen for kinase inhibitors in drug discovery, and explore its involvement in DNA repair processes, particularly through phosphorylation of nucleotide excision repair factors.
Its applications extend to cancer research, as CDK7/CCNH is a therapeutic target for malignancies driven by transcriptional addiction. Recombinant CCNH also serves as a tool for structural studies, antibody production, and elucidating molecular mechanisms underlying cell cycle checkpoints. The availability of purified, high-quality recombinant CCNH accelerates mechanistic studies and therapeutic development, highlighting its importance in both basic and translational biomedical research.
×
